KRAS and familial pancreatic carcinoma: These results indicate that DEG-KRAS is broadly effective across multiple KRAS-mutant pancreatic cancer cell lines and that its antiproliferative effects are potentiated in contexts where adhesion-mediated survival signals are disrupted.